Buradasınız

Henoch-Schönlein Purpura’lı bir Olguda Azatiyopirin’e bağlı Alopesi

Azathioprine-associated Alopecia in a Patient with Henoch-Schönlein Purpura

Journal Name:

Publication Year:

Abstract (2. Language): 
Henoch-Schönlein (HSP) purpura is a small vessel vasculitis affecting the skin, joint, gut, and kidneys. Azathioprine is a drug used to prevent rejection after solid organ transplantation and treat autoimmune-inflammatuar diseases. It has been reported that corticosteroid and AZA have some useful effect in HSP nephritis without renal dysfunction. AZA-associated side effects such as myelosupression, hepatotoxicity, pancreatitis, skin rash, fever, nausea, and abdominal pain often develop during the therapy. We report a case of alopecia as a rare complication of AZA therapy.
Abstract (Original Language): 
Henoch-Schönlein purpurası (HSP), deri, eklem, sindirim sistemi ve böbrekleri etkileyen bir küçük damar vaskülitidir. Azatiyopirin (AZA), solid organ transplantasyonlarından sonra rejeksiyonu önlemek ve otoimmün-inflamatuar hastalıkları tedavi etmek için kullanılan bir ilaçtır. Kortikosteroid ve AZA’nın böbrek fonksiyon bozukluğunun olmadığı HSP nefritinde faydalı etkileri bildirilmiştir. AZA ile ilişkili kemik iliği baskılanması, karaciğer toksisitesi, pankreatit, deri döküntüleri, ateş, kusma, karın ağrısı gibi komplikasyonlar tedavi sırasında sıklıkla gelişmektedir. Burada, AZA tedavisinin az rastlanan bir komplikasyonu olan alopesi gelişen bir olgu sunulmuştur
133-135

REFERENCES

References: 

1. Feehally J, Floege J: IgA nephropathy and Henoch-
Schönlein nephritis. In: Feehally J, Floege J, Johnson
RJ (eds), Comprehensive Clinical Nephrology (3 th ed).
Mosby Elsevier, Philadelphia 2007; 253-264
2. Foster BJ, Bernard C, Drummond KN, Sharma AK:
Effective therapy for severe Henoch-Schonlein purpura
nephritis with prednisone and azathioprine: A clinical and
histopathologic study. J Pediatr 2000; 136: 370-375
3. Sood A, Midha V, Sood N, Bansal M: Long term results
of use of azathioprine in patients with ulcerative colitis in
India. World J Gastroenterol 2006; 12: 7332-73364. Demirtaş-Ertan G, Rowshani AT, ten Berge IJ: Azathioprineinduced
shock in a patient suffering from undifferantiated
erosive oligoarthritis. Neth J Med 2006; 64: 124-126
5. Colli MV, Amaro TA, Pinto AL, Gaburri PD, Fonseca Chebli
JM: Azathioprine toxicity in Crohn’s disease: Incidence,
approach and course. Rev Assoc Med Bras 2008; 54: 415-
421
6. Al Hadithy AF, de Boer NK, Derijks LJ, Escher JC, Mulder
CJ, Brouwers JR: Thiopurines in inflammatory bowel
disease: Pharmacogenetics, therapeutic drug monitoring
and clinical recommendations. Dig Liver Dis 2005; 37:
282-297
7. Shin JI, Park JM, Shin YH, Kim JH, Lee JS, Kim PK, Jeong
HJ: Can azathioprine and steroids alter the progression of
severe Henoch-Schönlein nephritis in children? Pediatr
Nephrol 2000; 20: 1087–1092

Thank you for copying data from http://www.arastirmax.com